تداخلات تريبروستينيل

…fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.8 , 5.9) ] • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product [see Warnings and Precautions (5.8 , 5.10) ] • Pregnancy ( 4 ) (نشرة ديكلوفيناك وميزوبروستول، موانع الاستعمال)

Ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of uterine hemorrhage. (نشرة كيتورولاك، موانع الاستعمال)

The combined use of two or more prostaglandins, or prostaglandin analogs including XELPROS is not recommended. (نشرة لاتانوبروست، التداخلات الدوائية)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (نشرة أتينولول، التداخلات الدوائية)

Concomitant use of prostaglandin synthase inhibiting drugs, e.g., indomethacin, may decrease the hypotensive effects of beta-blockers. (نشرة أتينولول وكلورثاليدون، التداخلات الدوائية)

Hypotension Adenosine injection is a potent peripheral vasodilator and can induce significant hypotension. (نشرة أدينوزين، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (نشرة أفانافيل، التحذيرات والاحتياطات)

Nonetheless, caution, as with any other peripheral vasodilator, should be exercised when administering amlodipine, particularly in patients with severe aortic stenosis. (نشرة أملوديبين وفالسارتان، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة إندوميثاسين، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة أوكسابروزين، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (نشرة إيبوبروستينول، التداخلات الدوائية)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة إيبوبروفين، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة إيبوبروفين وفاموتيدين، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة إيتودولاك، التحذيرات)

The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators. (نشرة إيزوسوربيد أحادي النترات، التداخلات الدوائية)

Drug Interactions The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators. (نشرة إيزوسوربيد ثنائي النترات، التداخلات الدوائية)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة باراسيتامول وإيبوبروفين، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة بيروكسيكام، التحذيرات والاحتياطات)

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (نشرة تادالافيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة تولميتين، التحذيرات)

Effect of Other Drugs on Treprostinil Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both C max and AUC) to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة حمض الميفيناميك، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة ديفلونيزال، التحذيرات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

• Co-administration with Other Vasodilators or Negative Chronotropic Agents : Use with caution due to additive pharmacodynamic effects. (نشرة ديكسميديتوميدين، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة ديكلوفيناك، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة سالسالات، التحذيرات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. (نشرة سولينداك، التحذيرات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة سوماتريبتان ونابروكسين، التحذيرات والاحتياطات)

Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. (نشرة سيلدينافيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة سيليكوكسيب، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (نشرة فاردينافيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة فلوربيبروفين، التحذيرات والاحتياطات)

Indomethacin Coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. (نشرة فوروسيميد، التداخلات الدوائية)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Antihypertensive Agents Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering blood pressure. (نشرة فيراباميل، التداخلات الدوائية)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة فينوبروفين، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Valvular Stenosis There is concern, on theoretical grounds, that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction as others. (نشرة كابتوبريل، الاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

A second form of renal toxicity has been seen in patients with conditions leading to a reduction in renal blood flow or blood volume, where renal prostaglandins have a supportive role in the maintenance of renal blood flow. (نشرة كيتوبروفين، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins. (نشرة ميثيل إرغونوفين، التداخلات الدوائية)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة ميلوكسيكام، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة نابروكسين، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة نابروكسين وإيزوميبرازول، التحذيرات والاحتياطات)

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة نابوميتون، التحذيرات)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Nifedipine is a vasodilator, and co-administration of other drugs affecting blood pressure may result in pharmacodynamic interactions. (نشرة نيفيديبين، التداخلات الدوائية)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Renal Toxicity and Hyperkalemia Renal Toxicity Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. (نشرة هيدروكودون وإيبوبروفين، التحذيرات)

The pharmacokinetics of R- and S- warfarin and the international normalized ratio (INR) in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 ng/kg/min. (نشرة تريبروستينيل، التداخلات الدوائية)

Drugs antagonizing pressor effects of epinephrine α-blockers, such as phentolamine Vasodilators, such as nitrates Diuretics Antihypertensives Ergot alkaloids Drugs potentiating pressor effects of epinephrine • Sympathomimetics • β-blockers, such as propranolol • Tricyclic anti-depressants • Monoamine oxidase (MAO) inhibitors • Catechol-O-methyl transferase (COMT)… (نشرة أدرينالين، التداخلات الدوائية)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Phosphodiesterase-5 (PDE5) Inhibitors: PDE5-inhibitors are also vasodilators. (نشرة ألفوزوسين، التحذيرات والاحتياطات)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (نشرة تريبروستينيل، التداخلات الدوائية)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (نشرة تريبروستينيل، التداخلات الدوائية)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (نشرة تريبروستينيل، التداخلات الدوائية)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (نشرة تريبروستينيل، التداخلات الدوائية)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (نشرة تريبروستينيل، التداخلات الدوائية)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (نشرة تريبروستينيل، التداخلات الدوائية)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة تامسولوسين، التحذيرات والاحتياطات)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (نشرة تريبروستينيل، التداخلات الدوائية)

Alpha-adrenergic antagonists and PDE-5 inhibitors are both vasodilators that can lower blood pressure. (نشرة دوتاستيريد وتامسولوسين، التحذيرات والاحتياطات)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. (نشرة سيلودوسين، التحذيرات والاحتياطات)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (نشرة تريبروستينيل، التداخلات الدوائية)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. (نشرة كلوريد البوتاسيوم، التداخلات الدوائية)

Post injury arterial injection of vasodilators and/or arterial infusion of parenteral fluids are generally regarded to be of no value in altering outcome. (نشرة ميثوهيكسيتال، التحذيرات)

Bronchospasm Like other inhaled prostaglandins, Tyvaso may cause acute bronchospasm. (نشرة تريبروستينيل، التحذيرات والاحتياطات)

Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. (نشرة تريبروستينيل، التداخلات الدوائية)